Treatment group:Infusion anti CD30 CAR T cells

2 trials

Sponsors

Tongji Hospital of Tongji University, Hubei Cancer Hospital

Conditions

CD30+ relapsed/refractory lymphoma

Early Phase 1

An exploratory clinical study to evaluate the safety and efficacy of anti-CD30 CAR T cell injection (anti CD30 CAR T cells) in patients with CD30+ relapsed/refractory lymphoma

RecruitingChiCTR2100053504

Tongji Hospital of Tongji UniversityCD30+ relapsed/refractory lymphoma

Start: 2021-11-30Updated: 2022-10-04

An exploratory clinical study to evaluate the safety and efficacy of anti-CD30 CAR T cell injection (anti CD30 CAR T cells) in patients with CD30+ relapsed/refractory lymphoma

RecruitingChiCTR2100053505

Hubei Cancer HospitalCD30+ relapsed/refractory lymphoma

Start: 2021-11-30Updated: 2022-10-04